Form 13-F position report

INTEGRA LIFESCIENCES HLDGS

Reported by BNP Paribas Asset Management Holding S A

IART 0.5 08/15/25 CUSIP 457985AM1 Manager CIK 0001520354

Reported 3,000,000 shares, down 1,500,000 (33.3%) from the prior quarter.

Reported value -34.3%; share count -33.3% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 3,000,000 Quarter-end amount reported
Reported value $2,831,000 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 4918000
2022-03-31 4721000
2022-06-30 4260000
2022-09-30 3935000
2022-12-31 4370000
2023-03-31 4361000
2023-06-30 4103000
2023-09-30 4110000
2023-12-31 4226000
2024-03-31 4311000
2024-06-30 2831000
2024-09-30 2851000
2024-12-31 2886000
2025-03-31 2947000
2025-06-30 2975000
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for INTEGRA LIFESCIENCES HLDGS held by BNP Paribas Asset Management Holding S A.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -3,000,000 (-100.0%) 0 $0 2025-11-07
Q2 2025 Unchanged 3,000,000 0 (0.0%) < 0.01% $2,975,000 2025-08-06
Q1 2025 Unchanged 3,000,000 0 (0.0%) < 0.01% $2,947,000 2025-05-14
Q4 2024 Unchanged 3,000,000 0 (0.0%) < 0.01% $2,886,000 2025-02-12
Q3 2024 Unchanged 3,000,000 0 (0.0%) < 0.01% $2,851,000 2024-11-08
Q2 2024 Reduced 3,000,000 -1,500,000 (-33.3%) < 0.01% $2,831,000 2024-07-30
Q1 2024 Unchanged 4,500,000 0 (0.0%) 0.01% $4,311,000 2024-05-08
Q4 2023 Unchanged 4,500,000 0 (0.0%) 0.01% $4,226,000 2024-02-09
Q3 2023 Unchanged 4,500,000 0 (0.0%) 0.01% $4,110,000 2023-11-13
Q2 2023 Unchanged 4,500,000 0 (0.0%) 0.01% $4,103,000 2023-08-08
Q1 2023 Unchanged 4,500,000 0 (0.0%) 0.02% $4,361,000 2023-05-08
Q4 2022 Unchanged 4,500,000 0 (0.0%) 0.02% $4,370,000 2023-02-10
Q3 2022 Unchanged 4,500,000 0 (0.0%) 0.02% $3,935,000 2022-11-10
Q2 2022 Unchanged 4,500,000 0 (0.0%) 0.02% $4,260,000 2022-08-04
Q1 2022 Unchanged 4,500,000 0 (0.0%) 0.02% $4,721,000 2022-05-12
Q4 2021 Unchanged 4,500,000 0 (0.0%) 0.02% $4,918,000 2022-02-09
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

48 managers reported INTEGRA LIFESCIENCES HLDGS for Q2 2024.

Managers reporting INTEGRA LIFESCIENCES HLDGS in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
DEERFIELD MANAGEMENT COMPANY L P SERIES C Added 174,364,000 +71,149,000 2.74% $164,540,507 2 qtrs
TENOR CAPITAL MANAGEMENT Co L P Added 80,661,000 +21,324,000 1.2% $76,527,124 12 qtrs
Linden Advisors LP Reduced 66,500,000 -1,000,000 0.53% $62,874,999 5 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Added 53,513,000 +3,000,000 1.62% $50,650,590 13 qtrs
Invesco Ltd Unchanged 52,000,000 0 0.01% $48,958,000 14 qtrs
LAZARD ASSET MANAGEMENT LLC Added 44,823,000 +7,909,000 0.05% $42,368,000 14 qtrs
MILLENNIUM MANAGEMENT LLC Unchanged 0 0 0.01% $30,247,302 2 qtrs
STATE STREET CORPORATION Added 12,384,000 +50,000 < 0.01% $11,710,374 14 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 10,156,000 -60,000 < 0.01% $9,581,011 14 qtrs
Opti Capital Management LP New 7,444,000 +7,444,000 0.52% $7,053,562 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
July 30, 2024
Filing type
13F-HR
Position type
NOTE 0.500% 8/1

Voting authority reported

Sole
0
Shared
40,722
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.